OurGLP1 archive
Page 3 of carefully sourced research, regulatory, safety and availability reporting.
Latest GLP-1 news30 July 2026
Oura's GLP-1 Insights combines logged doses, side effects and weight with wearable trends. Here is what the product does, how Lilly is involved and what has not yet been demonstrated.
Read the sourced summary29 July 2026
A careful look at the limited evidence on GLP-1 medicines, sexual desire and relationships, including a randomised dulaglutide trial and an FDA adverse-event database analysis.
Read the sourced summary29 July 2026
A Phase 2 apitegromab study and several registered trials show why obesity-drug research is looking beyond kilograms lost to lean mass, strength and physical function.
Read the sourced summary29 July 2026
A sourced roundup of new Retatrutide Phase 3 results, the US approval of oral orforglipron, Australian NAION warnings and an observational alcohol-hospitalisation study.
Read the sourced summary